Expression of p53 target genes segregates t(8;21) (and inv16) AML samples from the remaining AML patient samples. (A) Seven p53 target genes were chosen, based on published literature, and used in a principal component analysis on the published dataset of 130 AML patient samples (Table 2). CBF leukemias segregate from the other patient samples in a principle component analysis based on the expression of these p53 target genes. (B) Analysis of variance (7-way ANOVA) shows that t(8;21) patient samples have a significantly increased group mean expression level for the p53 target genes compared with other patient groups, excluding inv(16). Each dot represents differences in group mean value based on the 7 p53 target genes (y-axes) between t(8;21) AML and the other AML cytogenetic subtypes (noted on the x-axis). The bars represent 95% confidence intervals.